To Eunice E, Vlahos Ross, Luong Raymond, Halls Michelle L, Reading Patrick C, King Paul T, Chan Christopher, Drummond Grant R, Sobey Christopher G, Broughton Brad R S, Starkey Malcolm R, van der Sluis Renee, Lewin Sharon R, Bozinovski Steven, O'Neill Luke A J, Quach Tim, Porter Christopher J H, Brooks Doug A, O'Leary John J, Selemidis Stavros
Program in Chronic Infectious and Inflammatory Diseases, School of Health and Biomedical Sciences, College of Science, Engineering & Health, RMIT University, Bundoora, Victoria, 3083, Australia.
Department of Pharmacology, Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, 3800, Australia.
Nat Commun. 2017 Jul 12;8(1):69. doi: 10.1038/s41467-017-00057-x.
The imminent threat of viral epidemics and pandemics dictates a need for therapeutic approaches that target viral pathology irrespective of the infecting strain. Reactive oxygen species are ancient processes that protect plants, fungi and animals against invading pathogens including bacteria. However, in mammals reactive oxygen species production paradoxically promotes virus pathogenicity by mechanisms not yet defined. Here we identify that the primary enzymatic source of reactive oxygen species, NOX2 oxidase, is activated by single stranded RNA and DNA viruses in endocytic compartments resulting in endosomal hydrogen peroxide generation, which suppresses antiviral and humoral signaling networks via modification of a unique, highly conserved cysteine residue (Cys98) on Toll-like receptor-7. Accordingly, targeted inhibition of endosomal reactive oxygen species production abrogates influenza A virus pathogenicity. We conclude that endosomal reactive oxygen species promote fundamental molecular mechanisms of viral pathogenicity, and the specific targeting of this pathogenic process with endosomal-targeted reactive oxygen species inhibitors has implications for the treatment of viral disease.Production of reactive oxygen species is an ancient antimicrobial mechanism, but its role in antiviral defense in mammals is unclear. Here, To et al. show that virus infection activates endosomal NOX2 oxidase and restricts TLR7 signaling, and that an endosomal NOX2 inhibitor decreases viral pathogenicity.
病毒流行和大流行的紧迫威胁表明需要有针对病毒病理的治疗方法,而不考虑感染毒株。活性氧是古老的防御机制,可保护植物、真菌和动物抵御包括细菌在内的入侵病原体。然而,在哺乳动物中,活性氧的产生却通过尚未明确的机制反常地促进了病毒致病性。在此,我们发现活性氧的主要酶源——NOX2氧化酶,在内吞小室中被单链RNA和DNA病毒激活,导致内体过氧化氢生成,进而通过修饰Toll样受体7上一个独特的、高度保守的半胱氨酸残基(Cys98)来抑制抗病毒和体液信号网络。因此,对内体活性氧产生的靶向抑制可消除甲型流感病毒的致病性。我们得出结论,内体活性氧促进了病毒致病性的基本分子机制,用内体靶向的活性氧抑制剂特异性靶向这一致病过程对病毒性疾病的治疗具有重要意义。活性氧的产生是一种古老的抗菌机制,但其在哺乳动物抗病毒防御中的作用尚不清楚。在此,涂等人表明病毒感染激活内体NOX2氧化酶并限制TLR7信号传导,且内体NOX2抑制剂可降低病毒致病性。